In the midst of global economic uncertainty, the Government of Canada will continue to be inclusive – just as we have been throughout this period. By continuing to attract investment in research and development and manufacturing, we will continue to create good, quality jobs and build an economy that works for all Canadians.
The Prime Minister, Justin Trudeau, took part in the launch of Moderna’s modern mRNA vaccine in Laval, Quebec. When completed, the new facility will be able to produce 100 million mRNA vaccines each year and will create hundreds of good jobs. The Prime Minister also took the opportunity to remind Canadians to be aware of their COVID-19 vaccinations, including getting a booster shot if necessary to protect themselves and their loved ones.
The project is expected to be completed in 2024 at the earliest. In addition to the COVID-19 vaccine, they are expected to release vaccines for other respiratory diseases, such as influenza – pending their development by Moderna and approval by Health Canada.
During this pandemic, we worked tirelessly to secure protective equipment, invest in health care, and ensure that everyone in Canada who is eligible can receive the vaccine. As we move forward, we will strengthen our biomanufacturing and life sciences sectors to rebuild Canada’s vaccine manufacturing capabilities, bring Canadian innovation to the forefront of tomorrow’s healthcare, and ensure we are well prepared for the health challenges of the future – all while growing. economy and create good jobs.
“The COVID-19 vaccine saved lives and got Canadians back to doing what they love. Establishing these vaccine centers is a critical step in ensuring that Canadian workers and Canadian innovation play a critical role in protecting our communities and creating an economy that works for all. Canadians.”
“Today’s opening of Moderna’s facility in Laval brings us closer to seeing the future of vaccine manufacturing here in Canada. With talented employees, researchers and students, Laval will play a major role in global health and wellness. Moderna’s presence in Canada will strengthen our biomanufacturing ecosystem.” , and position the entire sector to continue to grow and create more jobs across the country.”
“Vaccine awareness is one way to prevent serious illness, hospitalization, and death from COVID-19. By promoting Canadian manufacturing jobs, we are strengthening domestic defense and pandemic preparedness by providing access to timely, up-to-date vaccines who help us save lives.”
“Our government continues to ensure that Canadians have access to the latest vaccines now and in the future. The establishment of this new facility is another important step in our partnership with Moderna to develop domestically produced mRNA vaccines. Having a vaccine made in Canada will help ensure we are prepared in the event of a pandemic.” future. We have, and will continue to strive to protect the health and safety of everyone in Canada.”
“I am delighted that we were able to attract Moderna to Laval. Its arrival strengthens Laval’s already established biopharmaceutical sector and kickstarts Phase II of Biotech City.
“Today is another important milestone for Moderna and our long-term partnership with the Government of Canada to support pandemic preparedness. We are moving quickly to ensure that mRNA vaccines are available to Canadians, with the goal of completing our manufacturing facility in Quebec by the end of 2024.”
- Moderna is a company pioneering mRNA therapeutics and vaccines. In August 2021, the Government of Canada announced a memorandum of understanding with Moderna to build an mRNA vaccine manufacturing facility in Canada. In April 2022, the Prime Minister announced plans to build a new building in Quebec. Since then, a definitive agreement has been concluded between the Government of Canada and Moderna.
- Moderna is partnering with Canada’s leading universities and organizations to help advance high-quality research and development here at home.
- Through the Strategic Innovation Fund, the government has supported projects from coast to coast to coast. These include $415 million to help Sanofi build an influenza vaccine manufacturing facility in Toronto, Ontario; up to $175.6 million to AbCellera for its antibody therapy research and construction of an antibody manufacturing facility in British Columbia; $39.8 million for BioVectra to build a state-of-the-art facility in Prince Edward Island and renovate their facility in Nova Scotia.
- The government has also invested $126 million to build a new Biology Manufacturing Center at the National Research Council’s Royalmount site in Montreal. The center received a license to launch the drug in August 2022 and will be able to produce a large number of vaccines, end-to-end – about 24 million doses per year.
- The 2021 budget provided $2.2 billion over seven years to expand the family life sciences standard and prepare for the pandemic. This funding will help build Canada’s talent pipeline and research pipeline, and promote the growth of Canada’s science industry.